key: cord-0941621-ttdhwkvg
authors: Brim, Anas; Ashktorab, Yusuf; Russo, Tiziano; Pizuorno, Antonio; Oskruchi, Gholamreza; Brim, Hassan
title: Pediatric COVID-19 and Gastrointestinal Symptoms in Africa
date: 2021-08-19
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.08.020
sha: 7824bb09cae85e94b78563d1c2eb3ab165f3c109
doc_id: 941621
cord_uid: ttdhwkvg

One year into the coronavirus disease 2019 (COVID-19) pandemic, the African continent still seems to be spared from the devastating effects the disease had in other continents. Africa's COVID-19 seems to be of a milder nature both in adults and children. However, lack of data from Africa is significant, and more studies are needed to validate the disease status, clinical manifestations, and future implications for Africa. In this study, we report pediatric COVID-19 features in Africa represented by 8 countries.

One year into the COVID-19 pandemic, the African continent still seems to be spared from the devastating effects the disease had in other continents. Africa's COVID-19 seems to be of a milder nature both in adults and children. However, lack of data from Africa is significant and more studies are needed to validate the disease status, clinical manifestations and future implications for Africa. In this study, we report pediatric COVID-19 features in Africa represented by 8 countries.

We conducted a systematic literature review(March 2020-November 2021), using the following terms: COVID-19 Africa, COVID-19 Africa Pediatrics, and COVID-19 Africa Children. Case characteristics (10 studies/8 counries, 294 patients positive for SARS-CoV-2-PCR, Table 1, Supplement) were described.. Symptoms and comorbidities were combined, compared, and analyzed by weighted analysis methods. SPSS version 26 was used for this analysis.

Ethiopian cases were the oldest. The mean age of our cohort was 11.4 years with a minimum of 5.75 years and a maximum of 15 years. The patients from Ethiopia (Table 1 , Suppl. Fig. 1 ) had an average of 15 years old followed by Morocco with 13 years old. The youngest cohort was from Sierra Leone with 5.75 years old. Females made 55% of our cohort. Gender distribution was not uniform, the Tunisian cohort was 87.5% males while the South African was 73.9% females. No deaths were reported in the overall cohort.

Fever was the most common symptom. Fever was present in 24.6% of the cohort. Its distribution was 19.9% in the Moroccan cohort, 5.6% in Ethiopia, and up to 100% in South African and Tunisian cohorts. Cough was present in 20% of our African cohort, ranging from 2.2% in Sierra Leone to 22.5% in the Nigerian cohort . Dyspnea was present in 8.5% (25% in Cameroon cohort) and myalgia in 60.8%. Interestingly, there were 63% asymptomatic cases. The Egyptian cohort had 100% asymptomatic cases while Nigeria and Sierra Leone reported 33% and 22%, respectively.

Diarrhea and abdominal pain were frequent. Our cohort had an 18.4% diarrhea prevalence, with highest prevalence (87.5%) in Tunisia and lowest (6.7%) in Morocco. Abdominal pain was present in 16.7% with a prevalence of 100% in Tunisia and 1.3% in Morocco. Nausea was present in 8% and vomiting in 4.9%. Nausea was noted in 50% in the Tunisian cohort while 4.4% and 5.7% had vomiting in Ethiopia and Nigeria, respectively. Least common symptom was anosmia with 4.3% with the highest prevalence of 5.8% in Morocco (Table 1 , Suppl. figure 2 ). Other symptoms. The studies from South Africa and Tunisia had more reported symptoms, some of which were highly prevalent. Cumulatively, conjunctivitis was present in 64.5% of these two countries' cohorts. More specifically, it was reported in 65.2% in South Africa and 62.5% in Tunisia. Rash followed a similar profile, although at much higher cumulative prevalence of 87.1%. These prevalences were 87% and 87.5% for South Africa and Tunisia, respectively.

While HIV and Ebola viruses had major damaging effects in Africa, SARS CoV-2 seems to have a different profile. Indeed, more than 60% of African COVID-19 children were asymptomatic, this is in contrast to what has been reported in an Alberta, Canada study 1 with 33% asymptomatic cases. Compulsory viral vaccinations given routinely in early childhood in Africa 2 might be partially providing some level of resistance against SARS CoV-2 infections. The ACE2 gene expression in the nasal epithelium is highest in younger children and decreases with age 3 . This is likely a reason why pediatric cases in general and those in our study did not display significant respiratory symptoms, as the virus might have been handled by the pediatric immune system before reaching the lungs. A comparison of our African cohort with a US cohort of 6,581 pediatric cases 4 revealed different profiles with fever at 24.6% vs. 48%, cough at 20% vs. 37.6%, vomiting at 4.9% vs. 13.2% in African vs. US cases, respectively. These profiles seem to reflect a differences in the immediate response to infection between these two groups. Nausea was equally represented in the two cohorts (8% vs. 8.8%). Abdominal pain and diarrhea were more prevalent in the African cohort (16.7% vs.10.1% and 18.4% vs. 11%, respectively). Gastrointestinal symptoms have been reported as potential mitigators and attenuators of COVID-19 disease as they generally correlated with better outcome. Worth noting that conjunctivitis was highly prevalent at 64.5% compared to only 2.7% in US pediatric cases. This finding might have major consequences if not addressed adequately. It will be important to determine whether the conjunctivitis cases are of bacterial or viral origin as the bacterial ones are generally treatable, while viral ones might linger longer and be more damaging to patients' sight as it was reported for Ebola survivors who suffered from uveitis, even after treatment 5 .

Another prominent symptom in our African cohort was rash which was reported in 87.1% of the patients in the Tunisian and South African cohorts. . Studies from Europe have reported skin manifestations in pediatric COVID-19 patients 6 , bt not at such higher prevalence as in our African cohort. While skin rash can result from extreme immune reactions, it might also reflect potential viral-induced liver function alterations 7 . However, we do not have any lab test results to assess liver function in our cohort. Limitations of our study include small size cohort and low number of included countries. We did however include all published reports. Reports from different countries do not have the same set of data, some being more comprehensive than others. Prospective studies need to include standardized protocols developed by the World Health Organization, especially for pandemic diseases.

In conclusion, this is the first African pediatric COVID-19 meta-analysis that shows that African pediatric COVID has a distinguishable profile with more pronounced gastrointestinal symptoms such as diarrhea and abdominal pain that likely attenuate the disease severity. Conjunctivitis and skin rash were prominently present in our cohort and deserve more attention and follow-up. Cough, fever and shortness of breath were less prevalent in our cohort. As a sign of pediatric African resilience, the level of asymptomatic cases was notable, in comparison to other continents. 

Symptoms associated with a positive result for a swab for SARS-CoV-2 infection among children in Alberta

Routine childhood immunization may protect against COVID-19

Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study

COVID-19 Pediatric Patients: Gastrointestinal Symptoms, Presentations, and Disparities by Race/Ethnicity in a Large

Clinical Manifestations and Pathogenesis of Uveitis in Ebola Virus Disease Survivors

Skin manifestations of COVID-19 in children: Part 3

The itch of liver disease

Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans